Drugs / IMC-C103C
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03973333 | May 2019 → Sep 2023 | cancer | Immunocore Ltd | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMC-C103C | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03973333 ↗ |
| Modality | Protein / enzyme biologic | “IMC-C103C is an immune mobilizing monoclonal T cell receptor against cancer (ImmTAC ®)” NCT03973333 ↗ |
| Route | Intravenous | “administered intravenously (IV) and subcutaneously (SC) once weekly (Q1W)” NCT03973333 ↗ |
| Route | Subcutaneous | “administered intravenously (IV) and subcutaneously (SC) once weekly (Q1W)” NCT03973333 ↗ |